

1
2
3
4
5
6
7
8
9
10
11
12
13

MASSIVE TRANSFUSION PROTOCOL: A BOON FOR SALVAGING PATIENTS OF MASSIVE OBSTETRIC HEMORRHAGE

A PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE
CENTER

ABSTRACT

BACKGROUND: Maternal mortality remains a major global health issue, with obstetric hemorrhage as the primary cause. Timely and effective blood transfusion is crucial for maintaining organ perfusion and oxygenation. This study seeks to evaluate maternal outcomes, focusing on survival rates and life-threatening complications following massive blood transfusion.

MATERIALS AND METHODS: A prospective observational study was conducted between July 2022 to January 2024 in the Department of Obstetrics and Gynecology of Shree Krishna Hospital, Karamsad, Gujarat, India which is a rural tertiary care institute catering to Anand and Kheda districts of Central Gujarat. Data included in the study were age, socioeconomic status, parity, weeks of gestation, underlying comorbidities, cause of hemorrhage, mode of management, number and ratio of blood products transfused, and complications of Massive Transfusion (MT).

RESULTS: The MT utilization rate of our institute was 2.74%. The mean age of the study group was 27.3yrs with 84% belonging to the rural population. Out of all 58% were antenatal cases majority being multipara- 61.7%. Post-Partum Hemorrhage (PPH) was the most common cause of massive obstetric hemorrhage i.e. 42%. At the same time, the average time for issuing the first blood product was 12 min. Most cases could be managed conservatively -31 out of 81 using oxytocics and timely blood transfusion. Amongst the operative interventions, obstetric hysterectomy was done in 23.4 % of cases. The overall ratio of Packed Cell Volume (PCV): Fresh Frozen Plasma (FFP): Platelet Concentrate (PC): Cryoprecipitate (CP) in the study was **1:1.02:0.8:2**. In 46% of the cases, patients did not suffer from any MT-related complications; Transfusion Associated Circulatory Overload (TACO) was seen in 16% and Transfusion Related Acute Lung Injury (TRALI) in 7.4%. The mortality rate was 5%. Blood transfusion-related complications are observed more with PC, followed by FFP and RCC.

CONCLUSIONS: PPH was the leading cause of obstetric hemorrhage. Maternal morbidity and mortality can be significantly reduced through early referral to a tertiary care center, prompt administration of oxytocics, and the timely initiation of massive transfusion and surgical interventions for uncontrolled bleeding. Maintaining a blood product ratio of approximately 1:1.02:0.8 for packed red blood cells (PRBCs), fresh frozen plasma (FFP), and platelets helps prevent coagulopathy, ensures adequate tissue perfusion, and shields the patient from the detrimental cycle of sepsis, hypothermia, hemodilution, and shock. PRC transfusion was maximally responsible for TRALI.

14
15
16
17

Keywords: massive transfusion protocol, post-partum haemorrhage, obstetric haemorrhage, maternal morbidity, maternal mortality

18 **1. INTRODUCTION**

19 The Massive Transfusion Protocol represents a revolutionary approach to early, proactive
20 hemostatic resuscitation for patients at high risk of substantial blood loss over a short
21 timeframe. Massive transfusion is defined as administering more than 4 units of red cell
22 concentrates (RCC) within 1 hour or over 10 units within 24 hours, with massive blood loss
23 defined as exceeding 150 ml/hr or one blood volume within 24 hours^{1,2}. Severe obstetric
24 hemorrhage is a major global issue, significantly contributing to maternal morbidity and
25 mortality. Causes of obstetric hemorrhage include placenta previa, placenta accreta, atonic
26 and traumatic postpartum hemorrhage (PPH), uterine rupture, placental abruption, and
27 uterine inversion. There is a notable increase in the incidence of massive obstetric
28 hemorrhage, often associated with a higher rate of cesarean sections³.

29
30 **Haemostatic Resuscitation** is a key approach that focuses on achieving local surgical
31 haemostasis and mitigating coagulopathy by preventing hypothermia, acidosis, and ensuring
32 the timely replacement of coagulation factors such as fibrinogen. In the context of massive
33 obstetric hemorrhage (MOH), extensive bleeding leads to reduced blood flow to the uterus.
34 This diminished perfusion causes tissue hypoperfusion, which in turn increases the
35 production of thrombomodulin by vascular endothelial cells. Thrombomodulin activates
36 protein C, setting off a cascade of irreversible events that result in elevated fibrinogen
37 degradation products and impaired uterine contractions.^{4,5} These effects are common in both
38 atonic and traumatic postpartum hemorrhage (PPH), leading to rapid deterioration of the
39 patient's condition. Consequently, implementing a Massive Transfusion Protocol (MTP)
40 becomes a crucial strategy for effectively managing MOH.

41
42 Using a fixed ratio of red cell concentrate (RCC) to fresh frozen plasma (FFP) at 1:1, and a
43 RCC:FFP:Platelet ratio of 1:1:1, has been shown to provide a survival advantage within the
44 first 6-24 hours of massive hemorrhage, where mortality is primarily associated with
45 hypovolemic shock and its effects⁶. Since the pathophysiology of obstetric bleeding is similar
46 to that of severe trauma, applying a Massive Transfusion Protocol (MTP) with FFP/RCC or
47 RBC ratios similar to those used in trauma care could be beneficial for managing obstetric
48 hemorrhage⁷. To improve non-trauma MTPs, further prospective studies are needed to
49 validate these ratios and to develop screening or prediction tools that can identify which
50 patients will benefit most from MTP activation.

51
52 **1.1 Aims**

53 The present study to insight regarding maternal outcome, in the form of: life-threatening
54 complications and subsequent survival or mortality following a massive blood transfusion for
55 obstetric hemorrhage.

56 We secondarily also aimed to acquire information related to causes and management of
57 massive obstetric hemorrhage, optimum blood products ratio and the time interval between
58 requisition and receipt of the blood products.

59
60
61 **2. MATERIALS AND METHOD**

62
63 **2.1 Studydesign**

64 This is a prospectiveobservational study conducted in the Department of Obstetrics and
65 Gynecology in Pramukh Swami Medical College, Karamsad, Gujarat, India from July 2022 to
66 January 2024.

67
68 **2.2 Study Subjects**

69 Only Obstetric patients, both antenatal and postpartum, who had undergone massive
70 obstetric hemorrhage necessitating Massive Transfusion Protocol were included in the
71 study. Patients with gynecological hemorrhage were excluded in the study.

72

73 **2.3 Setting**

74 This prospective, observational study was conducted in the Department of Obstetrics and
75 Gynaecology of Shree Krishna Hospital Pramukh Swami Medical College, Bhaikaka
76 university, Karamsad, Anand, Central Gujarat, India. This is a 750-bedded tertiary care
77 institute that caters to Anand and Kheda districts, over an area of about 50 km radius.

78

79 **2.4 Data Setting**

80 Data of the patients who had received MT was retrieved from our files and A.D. Gorawala
81 blood bank. The following details about the patient were collected. The patient's detailed
82 performa included patient ID number, age, profession, socioeconomic status, gravida, parity,
83 details of current pregnancy, mode and time of delivery, cause of obstetric haemorrhage,
84 coagulation profile, the timing of onset of haemorrhage to the onset of MT interval, number
85 of blood products transfused, its relative ratio of RBC:FFP:Platelets and cryoprecipitates,
86 hospital stay, ICU stay, the occurrence of complications like TRALI (transfusion-associated
87 acute lung injury), TACO (transfusion-associated circulatory overload), Acute Renal
88 Shutdown, Blood transfusion reaction, the need for mechanical ventilation, the need of
89 dialysis and vital organ failure and the final outcome as survival or mortality.

90

91 **2.5 Ethical Clearance**

92 The data collection was started after approval of the institutional ethics committee-
93 **IEC/BU/136/Faculty/1/293/2022**, as it was a prospective and descriptive study, a waiver of
94 consent was requested.

95

96 **2.6 Statistical analysis**

97 Descriptive and multivariate logistic regression were used to analyse data by using the
98 SPSS 29 software. Indescriptive statistics mean [SD] and frequency [%] were used to depict
99 the baseline profile of the study participants. A p value <0.05 was considered as statistically
100 significant.

101

102

103

104

105 **3. RESULTS**

106

107 The study was conducted between July 2022 to January 2024. There were total 2956
108 obstetric admissions out of which 81 patients required massive blood transfusion which
109 accounts for 2.74% of the MTP utilization rates. Highlighting the demographical data, the
110 minimum age of the patients requiring MTP was 19yrs and the maximum age was 38yrs.
111 The mean age of the study population was 27.3 years.

112 Table 1 shows that out of the total 81 cases, 68 cases i.e. 84 % cases belonged to rural
113 area. Maximum number of patients belonged to middle class socioeconomic status i.e. 51
114 cases out of the total 81 cases (63%). Amongst the study cases, antenatal patients were in
115 the majority with 47 (58%) of the total cases, while the rest were post-partum patients.
116 Majority of the patients were multipara-50 (61.7%) followed by primipara cases being 21
117 (26%). Parity of more than 4 were considered to be grand multipara. Atonic postpartum
118 hemorrhage (PPH) was more common among multiparous women. The category of patients

119 under 20 weeks included those with missed or incomplete abortions, ruptured ectopic
 120 pregnancies, abdominal pregnancies, and early-diagnosed placenta accreta syndrome.
 121
 122 **TABLE 1: DEMOGRAPHIC VARIABLES**

VARIABLES	NO. OF PATIENTS (n=81)	PERCENTAGE (%)
AGE		
15-20	6	7.4
21-25	22	27.2
26-30	33	40.7
31-35	14	17.3
36-40	6	7.4
LOCALITY		
Rural	68	84
Urban	13	16
SOCIOECONOMIC CLASS		
Upper middle class	7	8.6
Middle middle class	51	63
Lower class	23	28.4
PREGNANCY STATUS		
ANC	47	58
PNC	34	42
PARITY		
Nullipara	10	12.3
Primipara	21	26
Multipara	44	54.3
Grand multipara	6	7.4
GESTATIONAL AGE AT PRESENTATION		
<20	6	13.3
20-28	3	6.6
28-37	23	46.65
37-42	15	33.3

>42	0	0
-----	---	---

123 At Shree Krishna Hospital, the largest proportion of patients requiring Massive Transfusion
124 Protocol (MTP)—26 cases, or 32%—had undergone a lower segment cesarean section
125 (LSCS). Most of these cases were complicated by antepartum hemorrhage, including
126 placenta previa, placental abruption, and placenta accreta syndrome, necessitating either
127 emergency or elective LSCS.

128 Additionally, 9 patients (11.1%) in the laparotomy category underwent procedures such as
129 uterine rupture repair, hemoperitoneum drainage, stepwise devascularization, or obstetric
130 hysterectomy. These cases included uterine rupture, ruptured ectopic pregnancy, abdominal
131 pregnancy, placenta accreta spectrum, and traumatic PPH.

132 **TABLE 2: CAUSES OF HEMORRHAGE**

CAUSES OF HEMORRHAGE	NO. OF CASES	PERCENTAGE
ATONIC/ TRAUMATIC PPH	29	37
ABRUPTIO PLACENTA	17	21
DIC/ HELLP/ THROMBOCYTOPENIA	17	21
PLACENTA ACCRETA SYNDROME	8	9.8
PLACENTA PREVIA	4	5
RUPTURED ECTOPIC	3	3.7
RUPTURED UTERUS	2	2.5
ABDOMINAL PREGNANCY	1	1.2
TOTAL	81	100

133

134 Table 2 shows that the most prevalent cause of massive obstetric hemorrhage was
135 postpartum hemorrhage (PPH), accounting for 37% of cases. This category includes those
136 cases specifically associated with atonic and/or traumatic PPH. Other contributors to PPH,
137 such as thrombin defects and retained placenta, are detailed in separate sections:
138 DIC/HELLP/thrombocytopenia (17 cases, 21%) and placenta accreta spectrum (PAS) (8
139 cases, 9.8%).

140 For cases of antepartum hemorrhage (APH), the most common cause was placental
141 abruption, occurring in 17 cases (21%), while placenta previa was observed in 4 cases (5%).
142 Abdominal pregnancy was the least common, with only 1 case out of the total 81 cases, and
143 ruptured ectopic pregnancy was noted in 3 cases.

144 Many patients presented with multiple overlapping comorbidities. A significant portion,
 145 66.6%, exhibited deranged coagulation profiles, which included conditions such as HELLP
 146 syndrome, DIC and thrombocytopenia. Among those with hypertensive disorders of
 147 pregnancy, preeclampsia was the most common condition necessitating massive
 148 transfusions, affecting 43.2% of the cases. Additionally, 31% of the patients had a history of
 149 previous lower segment cesarean sections (LSCS). Sepsis was observed in 24.7% of the
 150 patients upon admission, often associated with atonic, traumatic, or secondary postpartum
 151 hemorrhage (PPH), particularly in cases involving multiple per vaginal examinations. Four
 152 patients had pre-existing cardiac conditions, including rheumatic heart disease with post-
 153 valve replacement, ongoing anticoagulant therapy, as well as, peripartum cardiomyopathy
 154 (PPCM). Acute kidney injury (AKI) was present in 14.8% of patients on admission,
 155 characterized by elevated serum creatinine levels exceeding 1.5 mg/dL, primarily due to pre-
 156 renal factors like acute blood loss. Furthermore, 29.6% of patients were diagnosed with
 157 multiorgan dysfunction syndrome (MODS) upon admission, attributable to underlying
 158 conditions such as HELLP syndrome, preeclampsia, and eclampsia. This often involved the
 159 simultaneous impairment of multiple systems, including hematological, renal, liver function,
 160 cardiac, respiratory, and/or central nervous systems (CNS).

161 In this study, the majority of postpartum hemorrhage (PPH) cases were attributed to uterine
 162 atony - 50.6% . Traumatic PPH was observed in 12.3% . Additionally, 7.4% of cases
 163 involved both atonic and traumatic PPH. Coagulation disorders were present in 17.3% of the
 164 cases, encompassing issues such as clotting factor abnormalities and thrombocytopenia.
 165 Secondary PPH, occurring between 24 hours and 6 weeks postpartum, was identified in 5
 166 out of 81 cases. Other causes of PPH included ruptured ectopic pregnancies, placenta
 167 accreta spectrum (PAS), and abdominal pregnancies.

168 The shock index was the most frequently used parameter for assessing overall blood loss in
 169 patients. This index is calculated by dividing the pulse rate by the systolic blood pressure
 170 (SBP). In the majority of cases, 52% of patients had a shock index greater than 1. Those
 171 presenting with severe shock typically had experienced a loss of more than 30% of their total
 172 blood volume.

173 The average time from the collection of the blood sample to the issuance of the first blood
 174 product was 12 minutes, in this desperate requisition O Negative blood was issued.

175

176

177

178 **TABLE 3: ON ADMISSION LABORATORY PARAMETERS, INTERVAL BETWEEN**
 179 **ONSET OF MOH TO MTP AND TOTAL BLOOD PRODUCTS GIVEN**

LAB PARAMETERS	RANGE	MEAN	MEDIAN
HEMOGLOBIN (GM/DL)	1.8-13.9	6.5	6.5
PLATLET (/MM ³)	2000-3,98,000	139	136
PT	9.3-90	22.78	13.7

INR	0.79-9	1.93	1.17
APTT	14.1-135	41	28.8
FIBRINOGEN	30-580	212	188
CREATININE	0.24-4.7	0.98	0.71
K ⁺	3-6.8	4.15	4


INTERVAL BETWEEN ONSET OF MOH TO DECISION OF INITIATION OF MTP

TIME INTERVAL (HRS)	NO. OF PATIENTS	PERCENTAGE
0HRS	20	24.7
<2HRS	6	7.4
2-6HRS	41	50.6
6-12 HRS	10	12.3
>12 HRS	4	4.9

BLOOD PRODUCTS

	TOTAL	AVERAGE
PCV	388	4.8
FFP	402	5
PC	317	4
CP	736	9

181 Table 3 depicts the severity of anemia the patients presented with. The minimum was
 182 1.8gm/dl and the mean was 6.5gm/dl. One of the patients had a platelet count of 2000/mm³.
 183 Whereas one patient had a fibrinogen level of 30mg% on admission. This shows the
 184 extreme of the cases catered by the institute. All of the above-mentioned cases survived. In
 185 20 cases the onset of obstetric haemorrhage was within the hospital during vaginal delivery,
 186 LSCS or laparotomy so MTP could be initiated immediately. Such cases included both
 187 elective and emergency situations. However in maximum number of cases due to delayed



188 referral MTP could be initiated in 2-6 hrs(41 out of 81 cases).The total number of blood
 189 products given to 81 patients in the study were 1866, out of which 388 were PCV, 402 were
 190 FFP, 317 were PC and 736 were CP. The average number of PCVs, FFPs, PCs and CPs
 191 was thereby 4.8, 5, 4 and 9 respectively; this gave us a ratio of 1:1.02:0.8:2 of PCV:
 192 FFP: PC: CP transfusion, which means for every 50 units of PCV transfusion, 51 units of FFP, 40
 193 units of PC and 100 units of CP was required.

194 **FIGURE 1: SURGICAL INTERVENTIONS**

195 In the majority of cases, specifically 31 (38.2%), massive bleeding was successfully
 196 managed through the timely administration of oxytocics including oxytocin,
 197 methylergometrin, carboprost, carbetocin and misoprostol and the implementation of a
 198 massive blood transfusion protocol. This approach was crucial in preventing complications
 199 such as hypothermia, acidosis, and disseminated intravascular coagulation (DIC). As per
 200 Figure 1 when surgical interventions were necessary, obstetric hysterectomy was the most
 201 commonly performed procedure, with 16 total and 3 subtotal hysterectomies. Additionally,
 202 cervicovaginal exploration and intrauterine packing were used in 13.6% of the cases (11
 203 cases). Among the 81 cases reviewed, the SR cannula—a novel technique for managing
 204 atonic postpartum hemorrhage (PPH)—was employed in 5 cases (6.2%).

205 **TABLE 4: SPECIFIC COMPLICATIONS AFTER MASSIVE BLOOD TRANSFUSION**

206

COMPLICATIONS	NO. OF CASES	PERCENTAGE
TACO	13	16
TRALI	6	7.4
ELECTROLYTE IMBALANCE	2	2.4

207 Many of the complications are overlapping with patients showing more than 2 complications
208 at a time. Table 4 shows among those who developed complications, 13 patients (16%) had
209 transfusion-associated circulatory overload (TACO), and 6 patients (7.4%) had transfusion-
210 related acute lung injury (TRALI). Fluid management was closely monitored using the inferior
211 vena cava (IVC) status via bedside echocardiogram in the ICU. It is noteworthy that 46
212 patients (56.8%) had no complications.

213 Multiple organ dysfunction syndrome (MODS) was diagnosed in 41 patients likely due to the
214 severity of their preexisting conditions like preeclampsia, eclampsia, HELLP syndrome,
215 hepatic disorders of pregnancy and PPCM; they may act as a confounder so we cannot say
216 it was because of MT. Acute kidney injury (AKI) occurred in 6.2% of cases, primarily due to
217 acute blood loss and delayed referral; 33% of these AKI cases progressed to chronic renal
218 failure (CRF) requiring dialysis. Sepsis was observed in 7 patients (8.6%) by the end of the
219 massive transfusion (MT), resulting from either the progression of existing sepsis or
220 secondary infections related to prolonged hospital stays and invasive treatments like
221 ventilator-associated pneumonia (VAP). About 20% of the cases involved acute febrile
222 reactions, managed with antipyretics and antihistamines. The incidence of dilutional
223 coagulopathy decreased with the administration of blood products in a ratio of **1:1.02:0.8** for
224 packed cell volume (PCV), fresh frozen plasma (FFP), and platelet concentrates (PC). Most
225 post-MT complications were overlapping and related to the patients' underlying
226 comorbidities.

227 **TABLE 5: CORRELATION OF THE BLOOD PRODUCTS TO COMPLICATIONS**

RELATION OF BLOOD PRODUCTS TO COMPLICATIONS ADJUSTED WITH HIGH-RISK MATERNAL FACTORS ON ADMISSION				
	p-value	OR with 95% CI	95% C.I. for OR	
			Lower	Upper
RCC	0.371	1.235	0.777	1.962
FFP	0.772	1.030	0.829	1.287
PC	0.097	1.264	0.967	1.498
CP	0.539	1.033	0.936	1.134
DIRECT RELATION OF SPECIFIC BLOOD PRODUCT TO TRALI (TRANSFUSION-RELATED ACUTE LUNG INJURY) AND TACO (TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD)				
RCC	0.771	1.105	0.565	2.160

FFP	0.170	1.303	0.893	1.901
PC	0.080	1.351	0.964	1.892
CP	0.652	1.047	0.857	1.279

228

229 Table 5 shows the relation to the chances of development of transfusion-related
 230 complications after specific blood product transfusion which was adjusted to on-admission
 231 maternal high-risk factors like hypertensive disorders of pregnancy, sepsis, placenta accreta
 232 spectrum, previous caesarean status, abruption and HELLP syndrome. The maximum
 233 chances of blood complications occur due to PC transfusion. It also depicts that the
 234 maximum chances of TRALI and TACO are with PC.

235 The average number of days for total hospital stay that the patients requiring massive blood
 236 transfusion was 8.9 days. In 95% of the cases patients required intensive care monitoring as
 237 well in ICU. Average days for ICU admission were 3.6 days. Many of the patients required
 238 mechanical ventilation. Average number of days required for mechanical ventilation was on
 239 an average 1.9 days.

240 Out of the 81 cases, 95% were successfully treated due to the timely administration of
 241 oxytocics, higher antibiotics, and the effective support of a well-equipped blood bank and
 242 laboratory. This was possible due to multidisciplinary approach and efficient work of
 243 obstetricians, anesthesia, intensive care team and blood bank. While maintaining proper
 244 aseptic precautions thus minimizing hospital acquired infections. In 4 (5%) cases, patients
 245 succumbed to irreversible shock and could not be salvaged. In 60% of the cases baby could
 246 be saved due to prompt decision of LSCS. While 31% of the cases were IUFD more
 247 commonly due to APH – abruption more than placenta previa. 9% of the abortal cases
 248 include ectopic pregnancy, abdominal pregnancy and incomplete/ missed abortion with PAS.

249 **TABLE 6: COMPARISON OF RATIOS BETWEEN DIFFERENT STUDIES**

STUDIES	YEAR	CASES	PROTOCOL
Bonnet MP et al. ⁸	2011	38	FFP/RBC ratio exceeds 1 at 12 h following the onset of obstetric haemorrhage.
Matsunaga S et al. ⁹	2012	196	The medically necessary FFP/RCC ratio is 1.3 in obstetric haemorrhage.
Gutierrez MC et al. ¹⁰	2012	26	MTP was defined as a combination of 6 units of O-negative RBC, 4 units of FFP (liquid AB plasma or thawed type-specific plasma), and 1 apheresis platelet (PLT) unit.
Green L et al. ¹¹	2016	181	FFP/RBC ratio ≥ 1 is required during massive obstetrics haemorrhage.
Tanaka H et al. ¹²	2016	52	Transfusion of FFP/RBC ratio ≥ 1 reduces mortality

250

251 Table 6 compares the ratio of fresh frozen plasma (FFP) to red blood cells (RBC) across
 252 various studies. In present study, the ratio of FFP to packed cell volume (PCV), platelet
 253 concentrates (PC), and cryoprecipitate (CP) was 1.02:1:0.8:2. Several retrospective studies

254 have indicated that a higher plasma-to-RBC ratio in massive transfusion (MT) is linked to
255 improved survival rates in patients with traumatic injuries. Since 2007, there has been a
256 growing adoption of higher plasma-to-platelet-to-RBC ratios in MT therapy.

257

258 **4. DISCUSSION**

259 Trauma and obstetric patients have markedly different physiological profiles, which affect
260 hemorrhage management strategies. During pregnancy, physiological changes such as
261 hemodilution and increased cardiac output can mask significant bleeding, delaying detection
262 until hemoglobin and hematocrit levels drop significantly. Additionally, pregnancy-related
263 comorbidities can elevate the risk of severe bleeding, consumption coagulopathy, and the
264 early onset of organ failure and multiple organ dysfunction syndrome (MODS). These factors
265 necessitate distinct approaches to managing hemorrhage in obstetric cases compared to
266 trauma patients.

267 According to the RCOG's "Green-top Guideline: Blood Transfusion in Obstetrics" (October
268 2006), the recommended dosage for fresh frozen plasma (FFP) is 12-15 ml/kg for every 6
269 units of red blood cells (RBC). The guideline emphasizes using prothrombin time (PT) and
270 activated partial thromboplastin time (APTT) from coagulation tests as the primary indicators
271 for determining FFP requirements, with target levels set at 1.5 times the normal range for PT
272 and APTT, and a fibrinogen level of 150 mg/dl or higher. It also advises regular monitoring of
273 these tests and blood counts in cases of prolonged bleeding. Additionally, the guideline
274 recommends administering cryoprecipitate in two sets of five units to maintain fibrinogen
275 levels at or above 150 mg/dl.

276 The ACOG (May 2015) guidelines recommend an early and aggressive transfusion strategy
277 with a 1:1:1 ratio of red blood cells (RBC), fresh frozen plasma (FFP), and platelets (PC)
278 during massive transfusions. This approach aims to address coagulopathy, hypothermia,
279 and acidosis, which are critical factors that significantly increase the risk of patient
280 mortality¹³.

281 Poor outcomes following massive obstetric hemorrhage (MOH) and massive transfusion
282 (MT) are often due to delayed treatment, unavailability of blood products, inaccurate blood
283 loss estimation, lack of treatment protocols, and poor communication among team members.
284 In contrast, our study highlights that present institute has a benefit of a well-organized
285 multidisciplinary approach. This includes an equipped trauma care center, dedicated
286 obstetric team, efficient laboratory and blood bank services, anesthesia, operating theaters,
287 and a critical care team with ICU centers and dialysis units, all operating 24/7.

288 In the current study, 81 out of 2,956 obstetric admissions required massive blood transfusion
289 (MT), resulting in a utilization rate of 2.74%. This is higher than the 0.7% reported by Ochiai
290 D et al. in Japan¹⁴ but lower than the 3% observed by Paul I. Ramler et al. in the
291 Netherlands¹⁵. Notably, a 2020 study by S. Anuraga et al. in Puducherry¹⁶, India, reported a
292 much higher MT rate of 20%. The previous study at the same institute by Rumi
293 Bhattacharjee et al¹⁷ in 2017 had an MT rate of 2.4%. Regarding case distribution, the prior
294 study showed 60.9% antenatal and 39.1% postnatal cases, while the current study reports
295 58% antenatal and 42% postnatal cases. This slight shift, along with varying MT rates,
296 suggests evolving practices or patient profiles in obstetric care.

297 In the current study, the mean age of patients requiring massive blood transfusion (MT) was
298 27.3 years, with a range of 19 to 38 years. This is consistent with the mean age reported in
299 Puducherry, India, but lower than the 36.8 years observed in Japan and the 32 years in the
300 Netherlands. The previous study at the same institute noted that most patients were in the

301 21-30 years age group. These findings suggest that younger women are more commonly
302 affected in Asian countries, potentially due to earlier marriages and childbearing compared
303 to developed countries. Supporting this, Patricia et al. found that females under 20 years are
304 more susceptible to pregnancy complications, such as poor fetal growth and postpartum
305 hemorrhage (PPH). Additionally, a study on elderly primigravidas indicated that 3%
306 experienced antepartum hemorrhage and 3% had PPH, further highlighting the impact of
307 age on pregnancy outcomes.

308 As per the Quality Improvement Program survey conducted in American College of
309 surgeons, 2013 during the pre-hospital resuscitation the most common blood products used
310 were RBCs and plasma, while the most common intravenous hemostatic agent is
311 Tranexamic Acid. Hypotension with SBP \leq 100mmhg was the most common MTP trigger.
312 Laboratory values were infrequently used to initiate MT. Amongst the blood products plasma
313 is immediately available in <5 minutes. most common plasma type used is thawed plasma.
314 The most common FFP:RBC ratio in the first cooler is \geq 1. Use of cryoprecipitates is also
315 encouraged in MT. In the present institute the shock status of the patients was assessed by
316 shock index of the patient (Pulse/ SBP), urine output and by calculating the average amount
317 of blood loss of the patient. In the present institute the average time interval between the
318 blood collection and issuing of the first blood product is 12 min. The most common
319 hemostatic agent used is injectable TRANEXAMIC ACID followed by injectable
320 HEMOCOAGULASE (BOTROPACE). The facility of TEG (thromboelastography) is not
321 currently available in present institute.

322 Le Bas et al.¹⁸ recently highlighted that during pregnancy, the normal shock index (pulse rate
323 divided by systolic blood pressure) is typically higher compared to non-pregnant adults. This
324 increase is due to a higher pulse rate and a decrease in systolic blood pressure. An obstetric
325 shock index (OSI) greater than 1 is associated with a higher likelihood of requiring a blood
326 transfusion following postpartum hemorrhage (PPH). Consequently, the OSI can serve as a
327 useful bedside clinical tool for assessing the degree of blood loss, offering a more reliable
328 measure than visual estimation, which is prone to significant observer variability. The latest
329 Green Top Guideline from the Royal College of Obstetricians and Gynaecologists
330 underscores the importance of the OSI in identifying women at risk of adverse outcomes. In
331 the present study, 26% of patients were categorized with moderate shock (SI between 1 and
332 1.39), while another 26% were in severe shock (SI \geq 1.4). On average, patients with severe
333 shock experienced blood loss exceeding 30% of their total blood volume. As compared to
334 Rumi et al which was a retrospective study, blood products transfusion was decided by
335 physician whereas in the current study which is a prospective study the determinants for
336 blood transfusion were the clinical status of the patient and lab parameters including the
337 Shock Index(SI), coagulation profile and obstetric parameters.

338 As per literature, the proportion of patients with previous caesarean sections varies, with
339 Ramer et al. reporting 23%, S. Anuraga et al. indicating 33.3%, and the current study
340 showing a rate of 31%. A history of caesarean sections, along with prior myomectomy or
341 dilatation and evacuation, is linked to increased risks in subsequent pregnancies. These
342 risks include uterine rupture, dense adhesions, placenta previa, and placenta accreta
343 syndrome. Notably, the risk of placenta accreta syndrome rises with the number of previous
344 caesarean sections, thereby increasing the likelihood that a patient may require an obstetric
345 hysterectomy in future pregnancies.

346 Among the causes of obstetric hemorrhage, the single most common cause is post-partum
347 hemorrhage – which includes all the 4Ts -tone, thrombin, tissue and trauma. In the present
348 study (year 2022 to 2024) atonic PPH accounts for 50.6% of the cases while it was 33.5% in

349 previous study of the same institute (year 2014 to 2017 published in 2019). It was 58.3 % in
350 the study conducted in Japan and 57% in Netherlands study.

351 In the present study, peripartum hysterectomy was necessary in 23.4% of cases involving
352 obstetric hemorrhage. The primary causes for this intervention were atonic postpartum
353 hemorrhage (PPH), traumatic PPH, followed by placenta accreta syndrome and uterine
354 rupture. This rate is comparable to the 23% reported by Rumi Bhattacharjee et al. (2017) but
355 higher than the 11% observed in a study conducted in Puducherry. In contrast, rates in
356 developed countries vary significantly, with Ochiai D et al. reporting 4.2% and Paul I. Ramler
357 et al. reporting 30%. Peripartum hysterectomy is generally considered a last-resort surgical
358 intervention, employed when patients do not respond to aggressive medical management
359 and conservative organ-preserving techniques.

360 Mortality rates following peripartum hysterectomy differ markedly between developed and
361 developing countries. In developed nations, such as the Netherlands, mortality is low at
362 1.08%. However, in developing countries, rates are significantly higher, with 11.1% in
363 Puducherry, 10% in a previous study from the current institute, and 5% in the present study.
364 Common causes of mortality include MODS, ARDS, sepsis, and acute kidney failure.
365 Research suggests that early activation of massive transfusion protocols (MTP) and
366 improved antenatal care to identify high-risk patients can help prevent severe outcomes and
367 reduce mortality

368 In the current study, among 81 cases, 46 (56.8%) did not experience complications related
369 to massive blood transfusion. This favorable outcome is attributed to effective fluid
370 management, monitored through the patient's IVC status using a bedside ECHO machine in
371 the ICU. Among the complications, Multiple Organ Dysfunction Syndrome (MODS) was the
372 most common, likely due to the underlying pathophysiology of the patients. Transfusion-
373 related acute lung injury (TRALI) was observed in 7.4% of cases, while transfusion-
374 associated circulatory overload (TACO) occurred in 16%.

375 The risk of TRALI varies by blood product, with one case per 5,000 PRBCs, one per 2,000
376 FFP, and one per 400 platelets¹⁹⁻²¹. A recent ICU study found an 8% incidence of TRALI,
377 with platelet or FFP transfusions increasing the risk nearly threefold. In present study, the
378 odds ratios for developing TRALI were 1.351 for platelet transfusions, 1.303 for FFP, 1.105
379 for PRBCs, and 1.047 for cryoprecipitate. Dilutional coagulopathy was observed in only 16%
380 of cases, as the PCV:FFP ratio is maintained at 1:1:1. Fibrinogen replacement, through
381 cryoprecipitate or fibrinogen concentrate, has proven effective in managing obstetric
382 hemorrhage and other conditions, with several studies supporting its efficacy. As per a study
383 conducted in Department of Obstetrics and Gynecology, Baylor College of Medicine,
384 Houston, Texas between 2014-2020 uterine atony was found to be the commonest etiology
385 for massive hemorrhage (34%), followed by placenta accreta spectrum (32%). A mean of 6.5
386 units of packed red blood cells, 14.8 units of fresh frozen plasma and cryoprecipitate, and
387 8.3 units of platelets were transfused per patient²².

388 **5.CONCLUSION –**

389 In the present study, the utilization rate of the massive transfusion protocol (MTP) was
390 2.74%. Postpartum hemorrhage (PPH) emerged as the primary cause of obstetric
391 hemorrhage. To enhance maternal morbidity and mortality outcomes, early referral to tertiary
392 care centers, timely administration of oxytocics, and the prompt initiation of MTP and
393 surgical interventions are crucial in managing cases of uncontrolled bleeding.

394 Maintaining a blood product ratio of 1:1.02:0.8 for PCV:FFP:Platelets proved effective in
395 preventing coagulopathy, ensuring adequate tissue perfusion, and protecting patients from
396 the detrimental cycle of sepsis, hypothermia, hemodilution, and shock. MT related
397 complications were managed by assessing fluid status through chest auscultation and
398 bedside ECHO for IVC status in the ICU, which provided valuable guidance in managing
399 these complications.

400 Additionally, slightly increasing the proportion of FFP transfusion relative to PCV, as
401 determined by interval blood testing, can support early hemostasis. This approach helps in
402 optimizing the balance of blood products and improving overall patient outcomes during
403 massive transfusions. All the facilities serving obstetric patients must have an established
404 protocol so that prompt treatment of obstetric patients can improve their survival.
405

406 **ACKNOWLEDGEMENTS**

407
408 We express our sincere thanks to the Dean of Pramukhswami Medical College,
409 Superintendent of Shree Krishna Hospital, Karamsad and Provost of Bhaikaka University,
410 Karamsad for pratonage, permission and provision of all infrastructure facilities to undertake
411 this study and for letting me use patient details.

412 **COMPETING INTERESTS**

413
414 Authors have declared that no competing interest exist.
415

416 **AUTHORS' CONTRIBUTIONS**

- 417
- 418 • Dr. SmrutiBVaishnavhas helped in conceiving the idea, analysis, manuscript;
 - 419 • Dr. Rashmita Pal has written the project, done the data collection, analysis and has
420 written the manuscript.
 - 421 • Dr. Sangita Pandey has also contributed in writing the project, in analysis, and
422 writing the manuscript.
 - 423 • Mr. Mayur Shinde has helped with the statistical data analysis.
 - 424 • Dr. AkshayPadaliya has contributed in data collection and writing the manuscript.
425

426 **CONSENT**

427
428
429 Thiswasanobservationalstudy. Dataofthepatientswerecollectedfromthefileofthepatients.
430

431 **ETHICAL APPROVAL**

432
433
434 The data collection was started after approval of the institutional ethics committee-
435 **IEC/BU/136/Faculty/1/293/2022**, as it was a prospective and descriptive study, a waiver of
436 consent was requested.
437

438 ***Authors contributions***

439 ^a*Conceiving the idea, analysis, manuscript*

440 ^b*Writing the project, data collection, analysis, manuscript*

441 ^c*writing the project, analysis, manuscript*

442 ^d*statistical data analysis*

443 ^e*data collection, manuscript*

444

445

446 **DISCLAIMER**

447

448 Author(s) hereby declare that NO generative AI technologies such as Large Language
449 Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during
450 writing or editing of manuscripts.

451

452 **REFERENCES**

453 1. Fabry SM Sheldon GF, et al. Massive transfusion in the surgical patient; American
454 association of blood bank 1994; 135-156.

455 2. Balasudha K panikar S massive obstetric haemorrhage; Our experiences,
456 International Journal of Reproduction, Contraception, Obstetric and gynaecology
457 2014 March; 3(1).

458 3. Gungar T Smisek A et al. Surgical treatment of interactable postpartum
459 haemorrhage and changing trends in medium Obstetric perspective. Arch
460 Gynaecology obstetric 2009; 280; 351-355 DOI:10:1007 / s00404-008-0914%.

461 4. Ickx BE, Fluid and blood transfusion management in obstetrics. Eu Anaesthesiology
462 2010;27:1031-5.

463 5. Brohik, Cohen M J Devenport RA Acute coagulopathy of trauma: mechanism,
464 identification and effect. Curr opinion critical care; 13:680-5.

465 6. Lloyed Ketcham, John R Hess Seppo Hippalenindicacious for early fresh frozen
466 plasma, cryoprecipitates nd Platelet transfusion in trauma; The journal of
467 trauma.01/7 /2006; 60 (6 suppl):551-8.

468 7. Hiroaki Tanaka, ShigetakaMatsunga, Tomoyuki Yamashita et al. A systemic review
469 of MTP in obstetrics. Taiwanese Journal of obstetrics and gynaecology. Sb
470 (2017)715-718.

471 8. M.P. Bonnet, C. Deneux-Tharaux, M.H. Bouvier-Colle Critical care and transfusion
472 management in maternal deaths from postpartum haemorrhage, Eur
473 JObstetGynecolReprodBiol, 158 (2011), pp. 183-188

474 9. S. Matsunaga, H. Seki, Y. Ono, H. Matsumura, Y. Murayama, Y. Takai, *et al.*,
475 A retrospective analysis of transfusion management for obstetric hemorrhage in a
476 Japanese obstetric center, ISRN ObstetGynecol, 2012 (2012), p. 854064

477 10. M.C. Gutierrez, L.T. Goodnough, M. Druzin, A.J. Butwick, Postpartum hemorrhage
478 treated with a massive transfusion protocol at a tertiary obstetric center: a
479 retrospective study, Int J ObstetAnesth, 21 (2012), pp. 230-235

480 11. L. Green, M. Knight, F. Seeney, C. Hopkinson, P.W. Collins, R.E. Collis, *et al.*, The
481 haematological features and transfusion management of women who required
482 massive transfusion for major obstetric haemorrhage in the UK: a population based
483 study, Br J Haematol, 172 (2016), pp. 616-624

- 484 12. H. Tanaka, S. Katsuragi, T. Ikeda, K. Osato, J. Hasegawa, M. Nakata, *et al.*,
485 Efficacy of transfusion with fresh-frozen plasma:red blood cell concentrate ratio of 1
486 or more for amniotic fluid embolism with coagulopathy: a case-control study,
487 *Transfusion*, 56 (2016), pp. 3042-3046
- 488 13. Cotton BA, Guy JS, Morris Jr JA, Abumrad NN. The cellular, metabolic, and
489 systemic consequences of aggressive fluid resuscitation strategies. *Shock*
490 2006;26:115e21.
- 491 14. Ochiai, D.; Abe, Y.; Yamazaki, R.; Uemura, T.; Toriumi, A.; Matsushashi, H.; Tanaka,
492 Y.; Ikenoue, S.; Kasuga, Y.; Tanosaki, R.; et al. Clinical Results of a Massive Blood
493 Transfusion Protocol for Postpartum Hemorrhage in a University Hospital in Japan:
494 A Retrospective Study. *Medicina* 2021, 57, 983. [https://doi.org/10.3390/](https://doi.org/10.3390/medicina57090983)
495 [medicina57090983](https://doi.org/10.3390/medicina57090983)
- 496 15. Ramler PI, van den Akker T, Henriquez DDCA, et al. Women receiving massive
497 transfusion due to postpartum hemorrhage: A comparison over time between two
498 nationwide cohort studies. *Acta ObstetGynecol Scand.* 2019;98(6):795-804.
499 doi:10.1111/aogs.13542
- 500 16. Anuragaa S, Chaturvedula L, Basavarajegowda A. Blood component therapy in
501 patients having massive obstetric hemorrhage in a tertiary care center in
502 Puducherry. *Asian J Transfus Sci* 2023;17:210-6.
- 503 17. Bhattacharjee R, Raithatha N, Sapre S. An Analysis of Large Volume Blood and
504 Blood Product Transfusion in Critically Ill Obstetric Patients: A Retrospective Study.
505 *J South Asian Feder Obst Gynae* 2019;11(3):148–152
- 506 18. Le Bas A, Chandraharan E, Addei A, et al. Use of the “obstetric shock index” as an
507 adjunct in identifying significant blood loss in patients with massive postpartum
508 hemorrhage. *Int J GynecolObstet* 2013;124(3):253–255. DOI:
509 10.1016/j.ijgo.2013.08.020.
- 510 19. GazmuriRJ ,Shakeri SA . Blood transfusion and the risk of nosocomial infection: an
511 underreported complication? *Crit Care Med* .2002 ; 30 (10): 2389 - 2391 .
- 512 20. Silliman CC , Paterson AJ , Dickey WO , et al . The association of biologically active
513 lipids with the development of transfusion-related acute lung injury: a retrospective
514 study .*Transfusion* .1997 ; 37 (7): 719 - 726 .
- 515 21. Wallis JP ,Lubenko A , Wells AW , Chapman CE . Single hospital experience of
516 TRALI .*Transfusion* .2003 ; 43 (8): 1053 1059 .
- 517 22. Salmanian B, Clark SL, Hui SR, et al. Massive Transfusion Protocols in Obstetric
518 Hemorrhage: Theory versus Reality. *Am J Perinatol.* 2023;40(1):95-98.
519 doi:10.1055/s-0041-1728833
- 520

521
522

ABBREVIATION

AKI	Acute Kidney Injury
ANC	Antenatal Care
APH	Antepartum Hemorrhage
APTT	Activated Partial Thromboplastin Time
ART	Artificial Reproductive Techniques
ATLS	Advanced Trauma Life Support
CP	Cryoprecipitate
DIC	Disseminated Intravascular Coagulation
FFP	Fresh Frozen Plasma
Hb	Hemoglobin
HDU	High Dependency Units
INR	International Normalized Ratio
IVC	Inferior Vena Cava
LSCS	Lower Segment Cesarean Section
MODS	Multiorgan Dysfunction Syndrome
MOH	Massive Obstetric Hemorrhage
MT	Massive Transfusion
MTP	Massive Transfusion Protocol
OSI	Obstetrics Shock Index
PC	Platelet Concentrate
PCV	Packed Cell Volume
PLT	Platelet
PNC	Postnatal Care
PPH	Postpartum Hemorrhage
PPROM	Preterm Premature Rupture Of Membranes
PROM	Premature Rupture Of Membranes
PT	Prothrombin Time
RBC	Red Blood Concentrates
RCC	Red Cell Concentrate

SI	Shock Index
SR canula	Samarth Ram suction canula
TEG	Thromboelastography
WHO	World Health Organization